loading page

The combination of alanine aminotransferase and cytokines could predict the hepatitis B s antigen reduction in chronic hepatitis B patients in antiviral therapy
  • +3
  • Qian Zhang,
  • Xiaoqing Liu,
  • Huimin Wang,
  • Jinjie Du,
  • Hong Ren,
  • Peng Hu
Qian Zhang
Chongqing Medical University Affiliated Second Hospital

Corresponding Author:331610287@qq.com

Author Profile
Xiaoqing Liu
Chongqing Medical University Affiliated Second Hospital
Author Profile
Huimin Wang
Chongqing Medical University Affiliated Second Hospital
Author Profile
Jinjie Du
Chongqing Medical University Affiliated Second Hospital
Author Profile
Hong Ren
Department of Infectious Diseases, Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education
Author Profile
Peng Hu
Department of Infectious Diseases, Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education
Author Profile

Abstract

Background & Aims: Hepatitis B s antigen (HBsAg) is an important reference for the amount of covalently closed circular DNA. Patients may benefit from low HBsAg levels. We evaluated changes in HBsAg and cytokines in chronic hepatitis B (CHB) patients with low HBsAg levels who underwent oral antiviral therapy. Methods: A total of 197 CHB patients with HBsAg < 3,000 IU/ml and HBV DNA ≤1,000 IU/ml after more than a year of antiviral therapy were divided into a nucleotide analogs (NAs) group and an entecavir (ETV) group. HBsAg levels were determined every 6 months until 42 months. The serum chemokine and cytokine levels at baseline and 6, 18, and 30 months among 54 hepatitis B e antigen (HBeAg)-positive patients were measured. Results: HBsAg loss (1.72%), HBsAg reduction below 100 IU/ml (13.79%) and HBsAg reduction ≥0.5 log10 (24.14%) occurred in the NAs group. The cumulative incidences of HBsAg reduction and the HBsAg change in the NAs group were better than those in the ETV group (P<0.05). HBsAg reduction ≥0.5 log10 was associated with NAs therapy, MDC, interleukin (IL) 4, IL23 and alanine aminotransferase (ALT) in baseline and ALT levels change>60 U/L during antiviral therapy (P<0.05). ALT change and IL4 level were identified as independent factors for HBsAg reduction (p=0.006; OR=30.491 [2.626-351.312], and p=0.027; OR=1.847 [1.071-3.186], respectively). Conclusions: NAs therapy had some advantages in promoting a reduction in HBsAg. In clinical practice, ALT, MDC, IL4, and IL23 may be biomarkers for predicting HBsAg reduction.